Chugai Pharmaceutical CHGCF Stock
Chugai Pharmaceutical Price Chart
Chugai Pharmaceutical CHGCF Financial and Trading Overview
| Chugai Pharmaceutical stock price | 38 USD |
| Previous Close | 38.26 USD |
| Open | 38.45 USD |
| Bid | 35.86 USD x 10000 |
| Ask | 38.5 USD x 20000 |
| Day's Range | 38.45 - 38.45 USD |
| 52 Week Range | 34.79 - 68.08 USD |
| Volume | 300 USD |
| Avg. Volume | 9.81K USD |
| Market Cap | 61.18B USD |
| Beta (5Y Monthly) | 0.563 |
| PE Ratio (TTM) | 20.094593 |
| EPS (TTM) | 1.85 USD |
| Forward Dividend & Yield | 0.83 (2.25%) |
| Ex-Dividend Date | December 31, 2026 |
| 1y Target Est | N/A |
CHGCF Valuation Measures
| Enterprise Value | -901408882688 USD |
| Trailing P/E | 20.094593 |
| Forward P/E | 24.13961 |
| PEG Ratio (5 yr expected) | 1.54 |
| Price/Sales (ttm) | 0.04556213 |
| Price/Book (mrq) | 4.760865 |
| Enterprise Value/Revenue | -0.671 |
| Enterprise Value/EBITDA | -1.329 |
Trading Information
Chugai Pharmaceutical Stock Price History
| Beta (5Y Monthly) | 0.563 |
| 52-Week Change | -20.25% |
| S&P500 52-Week Change | 15.83% |
| 52 Week High | 68.08 USD |
| 52 Week Low | 34.79 USD |
| 50-Day Moving Average | 42.05 USD |
| 200-Day Moving Average | 49.94 USD |
CHGCF Share Statistics
| Avg. Volume (3 month) | 9.81K USD |
| Avg. Daily Volume (10-Days) | 10.94K USD |
| Shares Outstanding | 1.65B |
| Float | 639.38M |
| Short Ratio | N/A |
| % Held by Insiders | 59.89% |
| % Held by Institutions | 19.83% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 138 |
| Trailing Annual Dividend Yield | 360.69% |
| 5 Year Average Dividend Yield | 168.00% |
| Payout Ratio | 0.4818 |
| Last Split Factor | 3:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 35.10% |
| Operating Margin (ttm) | 47.09% |
| Gross Margin | 71.34% |
| EBITDA Margin | 50.49% |
Management Effectiveness
| Return on Assets (ttm) | 17.05% |
| Return on Equity (ttm) | 23.49% |
Income Statement
| Revenue (ttm) | 1.34T USD |
| Revenue Per Share (ttm) | 815.96 USD |
| Quarterly Revenue Growth (yoy) | 17.80% |
| Gross Profit (ttm) | 958B USD |
| EBITDA | 678.05B USD |
| Net Income Avi to Common (ttm) | 471.37B USD |
| Diluted EPS (ttm) | 1.85 |
| Quarterly Earnings Growth (yoy) | 19.69% |
Balance Sheet
| Total Cash (mrq) | 962.57B USD |
| Total Cash Per Share (mrq) | 585.04 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.345 |
| Book Value Per Share (mrq) | 7.8084545 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 449.3B USD |
| Levered Free Cash Flow (ttm) | 332.3B USD |
Profile of Chugai Pharmaceutical
| Country | United States |
| State | N/A |
| City | Chuo |
| Address | Nihonbashi Mitsui Tower |
| ZIP | 103-8324 |
| Phone | 81 3 3281 6611 |
| Website | https://www.chugai-pharm.co.jp |
| Industry | Drug Manufacturers - General |
| Sector(s) | Healthcare |
| Full Time Employees | 5104 |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Q&A For Chugai Pharmaceutical Stock
What is a current CHGCF stock price?
Chugai Pharmaceutical CHGCF stock price today per share is 38 USD.
How to purchase Chugai Pharmaceutical stock?
You can buy CHGCF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Chugai Pharmaceutical?
The stock symbol or ticker of Chugai Pharmaceutical is CHGCF.
Which industry does the Chugai Pharmaceutical company belong to?
The Chugai Pharmaceutical industry is Drug Manufacturers - General.
How many shares does Chugai Pharmaceutical have in circulation?
The max supply of Chugai Pharmaceutical shares is 1.65B.
What is Chugai Pharmaceutical Price to Earnings Ratio (PE Ratio)?
Chugai Pharmaceutical PE Ratio is 20.54054000 now.
What was Chugai Pharmaceutical earnings per share over the trailing 12 months (TTM)?
Chugai Pharmaceutical EPS is 1.85 USD over the trailing 12 months.
Which sector does the Chugai Pharmaceutical company belong to?
The Chugai Pharmaceutical sector is Healthcare.
